Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Otros Autores: | |
| Formato: | Journal article |
| Lenguaje: | English |
| Publicado: |
European Centre for Disease Prevention and Control
2021
|
| _version_ | 1826281624363335680 |
|---|---|
| author | Kissling, E Hooiveld, M Sandonis Martín, V Martínez-Baz, I William, N Vilcu, A-M Mazagatos, C Domegan, L de Lusignan, S Meijer, A Machado, A Brytting, M Casado, I Murray, J-LK Belhillil, S Larrauri, A O'Donnell, J Tsang, R de Lange, M Rodrigues, AP Riess, M Castilla, J Hamilton, M Falchi, A Pozo, F Dunford, L Cogdale, J Jansen, T Guiomar, R Enkirch, T Burgui, C Sigerson, D Blanchon, T Martínez Ochoa, EM Connell, J Ellis, J van Gageldonk-Lafeber, R Kislaya, I Rose, AM Valenciano, M |
| author2 | I-MOVE-COVID-19 primary care study team |
| author_facet | I-MOVE-COVID-19 primary care study team Kissling, E Hooiveld, M Sandonis Martín, V Martínez-Baz, I William, N Vilcu, A-M Mazagatos, C Domegan, L de Lusignan, S Meijer, A Machado, A Brytting, M Casado, I Murray, J-LK Belhillil, S Larrauri, A O'Donnell, J Tsang, R de Lange, M Rodrigues, AP Riess, M Castilla, J Hamilton, M Falchi, A Pozo, F Dunford, L Cogdale, J Jansen, T Guiomar, R Enkirch, T Burgui, C Sigerson, D Blanchon, T Martínez Ochoa, EM Connell, J Ellis, J van Gageldonk-Lafeber, R Kislaya, I Rose, AM Valenciano, M |
| author_sort | Kissling, E |
| collection | OXFORD |
| description | We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals. |
| first_indexed | 2024-03-07T00:31:35Z |
| format | Journal article |
| id | oxford-uuid:7ffc4ed6-845f-4d1a-a4a5-12d220879f1a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:31:35Z |
| publishDate | 2021 |
| publisher | European Centre for Disease Prevention and Control |
| record_format | dspace |
| spelling | oxford-uuid:7ffc4ed6-845f-4d1a-a4a5-12d220879f1a2022-03-26T21:20:37ZVaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7ffc4ed6-845f-4d1a-a4a5-12d220879f1aEnglishSymplectic ElementsEuropean Centre for Disease Prevention and Control2021Kissling, EHooiveld, MSandonis Martín, VMartínez-Baz, IWilliam, NVilcu, A-MMazagatos, CDomegan, Lde Lusignan, SMeijer, AMachado, ABrytting, MCasado, IMurray, J-LKBelhillil, SLarrauri, AO'Donnell, JTsang, Rde Lange, MRodrigues, APRiess, MCastilla, JHamilton, MFalchi, APozo, FDunford, LCogdale, JJansen, TGuiomar, REnkirch, TBurgui, CSigerson, DBlanchon, TMartínez Ochoa, EMConnell, JEllis, Jvan Gageldonk-Lafeber, RKislaya, IRose, AMValenciano, MI-MOVE-COVID-19 primary care study teamI-MOVE-COVID-19 primary care study team (in addition to authors above)We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals. |
| spellingShingle | Kissling, E Hooiveld, M Sandonis Martín, V Martínez-Baz, I William, N Vilcu, A-M Mazagatos, C Domegan, L de Lusignan, S Meijer, A Machado, A Brytting, M Casado, I Murray, J-LK Belhillil, S Larrauri, A O'Donnell, J Tsang, R de Lange, M Rodrigues, AP Riess, M Castilla, J Hamilton, M Falchi, A Pozo, F Dunford, L Cogdale, J Jansen, T Guiomar, R Enkirch, T Burgui, C Sigerson, D Blanchon, T Martínez Ochoa, EM Connell, J Ellis, J van Gageldonk-Lafeber, R Kislaya, I Rose, AM Valenciano, M Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021 |
| title | Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021 |
| title_full | Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021 |
| title_fullStr | Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021 |
| title_full_unstemmed | Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021 |
| title_short | Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021 |
| title_sort | vaccine effectiveness against symptomatic sars cov 2 infection in adults aged 65 years and older in primary care i move covid 19 project europe december 2020 to may 2021 |
| work_keys_str_mv | AT kisslinge vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT hooiveldm vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT sandonismartinv vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT martinezbazi vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT williamn vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT vilcuam vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT mazagatosc vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT domeganl vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT delusignans vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT meijera vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT machadoa vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT bryttingm vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT casadoi vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT murrayjlk vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT belhillils vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT larrauria vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT odonnellj vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT tsangr vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT delangem vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT rodriguesap vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT riessm vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT castillaj vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT hamiltonm vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT falchia vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT pozof vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT dunfordl vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT cogdalej vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT jansent vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT guiomarr vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT enkircht vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT burguic vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT sigersond vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT blanchont vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT martinezochoaem vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT connellj vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT ellisj vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT vangageldonklafeberr vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT kislayai vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT roseam vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 AT valencianom vaccineeffectivenessagainstsymptomaticsarscov2infectioninadultsaged65yearsandolderinprimarycareimovecovid19projecteuropedecember2020tomay2021 |